vTv Therapeutics Inc. cotiza a 30.46 USD y tiene una capitalización bursátil de $120M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase acti…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.05 | $1.65 | $-0.58 |
| Estimado | $-1.18 | $-1.08 | $0.21 | $-1.09 |
| Sorpresa | — | +2.8% | +685.7% | +46.8% |
| Métrica | VTVT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -41.9% | -40.4% | -1.5% |
| ROA | -30.0% | -32.0% | +2.0% |
| Current Ratio | 13.54 | 2.84 | +10.70 |
| Debt / Equity | — | 0.28 | — |